noretreat/BDAZ - There is no question that more testing would be required on CKD and Dementia if we had a fail on the primary outcome. My point is that with good numbers for these sub studies is that the story is far from dead. We have talked on this forum many times about recapitalization and many more years of testing if the primary target is not hit. What we haven't talked about to much is the astronomical size of the market if they all hit.

tada